Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy

NCT02452463 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped low accrual

Conditions

Lung Non-Squamous Non-Small Cell Carcinoma
Radiation-Induced Pneumonitis
Stage II Lung Non-Small Cell Cancer AJCC v7
Stage IIA Lung Non-Small Cell Carcinoma AJCC v7
Stage IIB Lung Non-Small Cell Carcinoma AJCC v7
Stage III Lung Non-Small Cell Cancer AJCC v7
Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Stage IV Lung Non-Small Cell Cancer AJCC v7

Interventions

BIOLOGICAL: Durvalumab
DRUG: Nintedanib
OTHER: Placebo
PROCEDURE: Quality-of-Life Assessment

Sponsor

Roswell Park Cancer Institute

Collaborators

[object Object]